Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Real-estate / development arm associated with the MedLog Georgia pharma-logistics group.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 95 | 6,330 | 1,402 | 947 | 3,122 | 2,470 | nmf |
| Net Cash used in Investing Activities | 156 | 3,930 | 1,882 | 2,753 | 6,041 | 5,263 | nmf |
| Free Cash Flow (OCF − Capex proxy) | 61 | 2,400 | 480 | 1,805 | 2,919 | 2,793 | nmf |
| Net Cash from Financing Activities | 0 | 602 | 5 | 4,568 | 2,081 | 940 | +11.8% |
| Net Change in Cash (before FX) | 61 | 1,798 | 475 | 2,763 | 837 | 1,853 | nmf |
| Effect of FX on Cash | 221 | 812 | 200 | 426 | 21 | 22 | nmf |
| Net Change in Cash (incl. FX) | 282 | 2,610 | 275 | 2,337 | 858 | 1,875 | nmf |
| Cash at Beginning of Year | 2,664 | 2,946 | 337 | 612 | 2,949 | 2,091 | -4.7% |
| Cash at End of Year | 2,946 | 337 | 612 | 2,949 | 2,091 | 216 | -40.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →